Amgen Inc (AMGN)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account

Sell

$354.40

Buy

$356.83

arrow-up$5.79 (+1.66%)

Prices updated at 09 Apr 2026, 13:15 EDT

Prices minimum 15 mins delay

Prices in USD

Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.

NASDAQ

0.83%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Income statement

Year chevron-l-regular chevron-r-regular	2024	2025
	33,424m	36,751m
	20,566m	24,714m
	7,258m	9,080m
	21.71	24.71
	4,090m	7,711m
	13,356m	16,898m
Sales, General and administrative	7,096m	7,050m
Interest expenses	3,155m	2,755m
Provision for income taxes	519m	1,265m
Operating expenses	13,308m	15,634m
Income before taxes	4,609m	8,976m
Net income available to common shareholders	4,090m	7,711m
	7.62	14.33
Net interest income	-3,155m	-2,755m
Advertising and promotion	-	-
Net investment income, net	-	-
Realised capital gains (losses), net	-	-
Total benefits, claims and expenses	-	-
Earnings per share (diluted)	7.56	14.23
Free cash flow per share	11.6298	21.2995
Book value/share	14.0168	17.8526
Debt equity ratio	9.622086	5.775583

Balance sheet

Year chevron-l-regular chevron-r-regular	2024	2025
Current assets	29,030m	29,057m
Current liabilities	23,099m	25,489m
Total capital	62,426m	58,663m
Total debt	60,099m	54,604m
Total equity	5,877m	8,658m
Total non current liabilities	-	-
Loans	56,549m	50,005m
Total assets	91,839m	90,586m
Total liabilities	-	-
Cash and cash equivalents	11,973m	9,129m
Common stock	537m	539m

Cash flow

Year chevron-l-regular chevron-r-regular	2024	2025
Cash at beginning of period	10,944m	11,973m
Cash dividends paid	-4,832m	-5,124m
	10,394m	8,100m
Investments (gains) losses	-1,046m	-1,943m
	11,973m	9,129m
Net income	-	-
	11,490m	9,958m
	-1,096m	-1,858m

The figures shown in the tables are quoted in the currency of the stock selected.

Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.